Citation Impact
Citing Papers
The discovery and development of HMG-CoA reductase inhibitors.
1992
The UK Biobank resource with deep phenotyping and genomic data
2018 StandoutNature
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
2004 Standout
Chemoenzymatic Synthesis of Building Blocks for Statin Side Chains
2004
3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate β-Amyloid-Induced Microglial Inflammatory Responses
2005
The safety of statins in clinical practice
2007
Role of cholesterol in the function and organization of G-protein coupled receptors
2006
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Peripheral vascular disease and Type 2 diabetes mellitus
2000
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
1994
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
2001
The metabolic syndrome
2010 Standout
Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
2007
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
2002
The changing landscape of atherosclerosis
2021 StandoutNature
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
2007 Standout
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
2002 Standout
Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
2007
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial
2001
Isoprenoids as mediators of the biological effects of statins
2002
Discovery, biochemistry and biology of lovastatin
1988
Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity
2002
Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
2004
Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2
1998
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
2005
Multi-target therapeutics: when the whole is greater than the sum of the parts
2006
HMG-CoA Reductase Inhibitors and Myotoxicity
2000
Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM
1995
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
2004
Diabetes and Atherosclerosis
2002 Standout
The development of combination drugs for atherosclerosis
2003
Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment.
1989
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Regulation of the mevalonate pathway
1990 StandoutNature
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
2007
Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study
2001
Statin-Associated Myopathy with Normal Creatine Kinase Levels
2002 Standout
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
2002 Standout
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])
2003
Alzheimer's Disease
2010 Standout
Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
2004
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
2009 StandoutNobel
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
New and emerging data from clinical trials of statins
2004
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
1999 Standout
Heterozygous familial hypercholesterolaemia is associated with pathological exercise‐induced leakage of muscle proteins, which is not aggravated by simvastatin therapy
1995
Safety of Aggressive Lipid Management
2007
Statin-Associated Myopathy
2003
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials
2001
Myopathy Induced by HMG–CoA Reductase Inhibitors in Rabbits: A Pathological, Electrophysiological, and Biochemical Study
1998
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
2007 Standout
Points of control in inflammation
2002 StandoutNature
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Treatment Goals for Low-Density Lipoprotein Cholesterol in the Secondary Prevention of Coronary Heart Disease: Absolute Levels or Extent of Lowering?
1997
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
2004
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
2004 Standout
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Implantation and the placenta: key pieces of the development puzzle
1994 StandoutScience
Validating therapeutic targets through human genetics
2013
Simvastatin
1995
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
2005 Standout
Concise and highly efficient approach to three key pyrimidine precursors for rosuvastatin synthesis
2012
HDL, ABC Transporters, and Cholesterol Efflux: Implications for the Treatment of Atherosclerosis
2008
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis.
1992 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
1984
Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors
2000
Organic Photoredox Catalysis
2016 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
1989
Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome
2004
Metal-free, visible-light photoredox catalysis: transformation of arylmethyl bromides to alcohols and aldehydes
2014
Cholesterol increases kinetic, energetic, and mechanical stability of the human β2-adrenergic receptor
2012 StandoutNobel
Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
2001
The Role of Natural Product Chemistry in Drug Discovery
2004
Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers.
1984
Comparison of Plasma Profiles of Lovastatin (Mevinolin), Simvastatin (Epistatin) and Pravastatin (Eptastatin) in the Dog
1990
Total Synthesis of α-Pyrone Meroterpenoids, Novel Bioactive Microbial Metabolites
2005 StandoutNobel
Rosuvastatin calcium
2003
A Receptor-Mediated Pathway for Cholesterol Homeostasis
1986 StandoutScienceNobel
Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques
2001
Drug Discovery: A Historical Perspective
2000 StandoutScience
Ultrastructure of decidualization in the pseudopregnant rat
1983
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
2010
Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.
1986
Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S
2001
Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2‐Substituted‐Alkynyl‐1‐Sulfonyl Fluoride (SASF) Hubs
2020 StandoutNobel
Learning from the cerivastatin experience
2001
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
1983
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
2005
Effects of Intensive Glucose Lowering in Type 2 Diabetes
2008 Standout
Membrane-bound domain of HMG CoA reductase is required for sterol-enhanced degradation of the enzyme
1985 StandoutNobel
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
2003 Standout
Synergistic effect of HIF-1α gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia
2009 StandoutNobel
Lactone Pathway to Statins Utilizing the Wittig Reaction. The Synthesis of Rosuvastatin
2010
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol
2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial
2003
Reduction of Serum Cholesterol in Heterozygous Patients with Familial Hypercholesterolemia
1983
Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia
1984
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
2002 Standout
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
2004 StandoutScience
Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
1998
Statin-Induced Proinflammatory Response in Mitogen-Activated Peripheral Blood Mononuclear Cells through the Activation of Caspase-1 and IL-18 Secretion in Monocytes
2006
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Liver Transplantation to Provide Low-Density-Lipoprotein Receptors and Lower Plasma Cholesterol in a Child with Homozygous Familial Hypercholesterolemia
1984 StandoutNobel
Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation
2009
Works of Jonathan A. Tobert being referenced
Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S)
1998
Efficacy and long-term adverse effect pattern of lovastatin
1988
The clinical efficacy and safety of lovastatin and MK-733--an overview
1987
HMG-CoA reductase inhibitors
2001
The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day
1997
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
1999
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
1999
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial
2004
Lipid-lowering therapy for patients with or at risk of coronary artery disease
1996
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
2020
Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A Reappraisal
1996
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
2003
The Efficacy of Intensive Dietary Therapy Alone or Combined with Lovastatin in Outpatients with Hypercholesterolemia
1993
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
1998
Changes in Progesterone Receptor Levels During Deciduomata Development in the Pseudopregnant Rat1
1977
Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme a reductase
1982
Plasma mevalonate as a measure of cholesterol synthesis in man.
1984
A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).
2000
Changes in Estrogen Receptor Levels During Deciduomata Development in the Pseudopregnant Rat1
1977
Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial
1996
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
1982